Actively Recruiting
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
Led by Second Affiliated Hospital of Nanchang University · Updated on 2026-04-02
100
Participants Needed
1
Research Sites
176 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.
CONDITIONS
Official Title
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years
- BMI of 25 kg/m² or higher
- Diagnosed with type 2 diabetes mellitus according to Chinese guidelines
- HbA1c of 8.5% or less
- Diabetes duration of 3 months or less with no prior use of antihyperglycemic drugs
- Willingness to participate, follow treatment plan, attend follow-ups, and provide informed consent
You will not qualify if you...
- BMI less than 25 kg/m²
- Age under 18 years or over 75 years
- History of type 1 diabetes, acute pancreatitis, or diabetes due to pancreatectomy
- History of or planned bariatric surgery, recent weight loss attempts, or use of weight-loss medications in past 3 months
- Use of certain diabetes-related drugs (GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, thiazolidinediones) in past 3 months
- Pregnant, breastfeeding, or planning pregnancy during study
- Severe diseases affecting major organs like heart, brain, lungs, digestive system, kidneys, blood, nervous system, or cancer
- Personal or family history of medullary thyroid carcinoma
- Severe mental disorders or communication difficulties preventing study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Minde road No.1
Jiangxi, Nanchang, China, 330000
Actively Recruiting
Research Team
J
Jianping Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here